Sandoz today declared the US market introduction of bimatoprost ophthalmic solution, 0.03% (0.3 mg/mL), which is a generic version of Allergan’s Latisse.
Bimatoprost ophthalmic solution, 0.03%, is a prescription medicine indicated to treat hypotrichosis of the eyelashes by increasing their growth, including length, thickness, and darkness.
“The launch of bimatoprost is a significant expansion to our industry-leading portfolio of ophthalmic products,” said Peter Goldschmidt, President of Sandoz Inc. “By extending our ophthalmic offerings, Sandoz will increase patients’ entrance to an exhaustive range of quality medication at reasonable costs.”
As per IMS Health, US deals for Latisse were around USD 75 million for the year time frame finishing ending in October. Sandoz is advertising bimatoprost also called Sandoz generic Latisse in a similar 0.03% quality as the marked product.
Important Safety Information
If you use prescription products for eye pressure issues, use bimatoprost under specialist care. Bimatoprost may cause increased brown pigmentation of the colored part of the eye, which is likely perpetual. Eyelid skin obscuring may happen and might be reversible. Just apply at the base of the upper lashes. Try not to APPLY to the lower lid. Hair may grow on skin that bimatoprost much of the time contacts. In the event that you have eye issues/medical procedures, counsel your doctor about the use of bimatoprost. Regular reactions are itchy and red eyes. Whenever stopped, lashes gradually back to their previous appearance.
Warnings and Precautions:
Effects for Intraocular Pressure (IOP): In patients using Lumigan® or other prostaglandin analogs for the treatment of raised IOP, the attendant use of bimatoprost ophthalmic solution, 0.03% may meddle with the ideal decrease in IOP. Patients using prostaglandin analogs, including Lumigan®, for IOP decrease should just use bimatoprost ophthalmic solution, 0.03% in the wake of counseling with their doctor and ought to be monitored for changes to their IOP.
Increased iris pigmentation has happened when bimatoprost solution as directed.
Patients should be advised about the potential for increased brown iris pigmentation, which is probably going to be perpetual.
Bimatoprost has been reported to cause color changes (darkening) to periorbital pigmented tissues and eyelashes. The pigmentation is relied upon to increase as long as bimatoprost is managed, however has been reported to be an endless supply of bimatoprost in many patients.
There is the potential for hair growth to happen in areas where bimatoprost solution comes in repeated contact with skin surfaces. Apply bimatoprost ophthalmic solution just to the skin of the upper eyelid margin, at the base of the eyelashes.
Bimatoprost ophthalmic solution should be used with alert in patients with active intraocular irritation (e.g., uveitis) because the inflammation may be exacerbated.
Bimatoprost contains benzalkonium chloride, which might be consumed by soft contact lenses. Contact lenses ought to be expelled before the use of the solution and might be reinserted 15 minutes following its administration.
Adverse Reactions The most much of the time reported adverse occasions were eye pruritus, conjunctival hyperemia, skin hyperpigmentation, ocular irritation, dry eye manifestations, and erythema of the eyelid. These occasions happened in under 4% of patients.
Postmarketing Experience: The accompanying responses have been recognized during postmarketing use of bimatoprost ophthalmic solution in clinical practice: eye swelling, eyelid edema, hypersensitivity (local allergic reaction), expanded lacrimation, madarosis, and trichorrhexis (transitory loss of a couple of eyelashes to loss of segments of eyelashes and brief eyelash breakage, separately), periorbital and top changes related with an extending of the eyelid sulcus, rash (counting macular and erythematous), skin discoloration (periorbital), and blurred vision.